The research, conducted at a single Polish center and published in the journal Clinical Research in Cardiology, focused on a question that has lingered at the margins of Fabry research for years: does the dysfunction of the vascular endothelium—the delicate single-cell lining of arteries that regulates vessel tone, blood clotting, and inflammation—actually correlate with the measurable structural changes seen in the heart on echocardiography? The evidence addressing that question has been scarce, particularly when it comes to understanding whether men and women, who experience very different disease trajectories because of the X-linked inheritance pattern, show different relationships between vessel health and cardiac remodeling.

To answer it, the team recruited 31 patients with confirmed Fabry disease—17 men and 14 women—who had no history of cardiovascular events such as heart attack or stroke, meaning any abnormalities detected could be attributed to the disease process itself rather than to overt clinical complications. Each patient was compared with a control matched for age, sex, and body mass index, allowing the researchers to isolate the effects of Fabry disease from the ordinary wear and tear of aging and obesity. The participants then underwent a battery of carefully standardized vascular and cardiac tests designed to capture both the function and the structure of the cardiovascular system.

The centerpiece of the vascular assessment was flow-mediated dilatation, or FMD, a technique that has become the gold standard for non-invasively measuring endothelial function in humans. In this test, an inflatable cuff is placed around the forearm and inflated to cut off blood flow for several minutes. When the cuff is released, the sudden rush of blood into the arm creates shear stress on the brachial artery wall, which in a healthy vessel triggers the endothelium to release nitric oxide, a potent vasodilator. Ultrasound imaging captures the resulting expansion of the artery, expressed as the percentage change in diameter. A robust FMD response signals a healthy, responsive endothelium; a blunted response signals dysfunction and, epidemiological studies have repeatedly shown, elevated future cardiovascular risk.

The results were unambiguous. Fabry patients exhibited a 54.8 percent reduction in their FMD response compared with matched controls—a near-halving of the artery’s ability to dilate on demand. This is not a subtle statistical signal but a physiologically dramatic finding, indicating that the glycosphingolipid deposits accumulating in the endothelial cells of these patients are already crippling one of the body’s most important protective mechanisms. When the endothelium cannot produce nitric oxide in adequate amounts, arteries constrict more readily, platelets stick together more easily, and inflammatory cells migrate into vessel walls—each of which accelerates the process of vascular disease.

Complementing the FMD measurements, the researchers assessed intima-media thickness, or IMT, of the common carotid artery using high-resolution ultrasound. IMT measures the combined thickness of the two innermost layers of the artery wall, and its enlargement is widely regarded as a marker of early atherosclerosis and arterial remodeling. Here, too, the Fabry patients fared significantly worse: their carotid IMT was 25.0 percent greater than that of controls. Taken together, the two findings paint a coherent picture of a vascular system under dual assault—functionally impaired in its ability to dilate, and structurally thickened in a way that presages atherosclerotic disease. For patients who have never experienced a cardiovascular event, this combination represents a latent but substantial risk reservoir.

But the study’s most novel contribution lies in its integration of echocardiography, the ultrasound examination of the heart, into this vascular picture. Transthoracic echocardiography allows clinicians to measure the dimensions of the heart’s chambers, the thickness of the muscular walls, and the efficiency of the heart’s pumping and filling. In Fabry disease, the heart is one of the principal battlegrounds: glycosphingolipid deposits accumulate within cardiac muscle cells, leading to a characteristic thickening of the left ventricular wall—a condition that can mimic hypertrophic cardiomyopathy—as well as subtle distortions of cardiac mechanics that precede overt heart failure. Because the endothelium plays a role in regulating coronary blood flow and myocardial health, the researchers hypothesized that the degree of endothelial dysfunction might track with the degree of cardiac structural change.

The analysis confirmed that echocardiographic changes are indeed present in this cohort of event-free patients, and that these changes correlate with the vascular abnormalities in ways that illuminate the natural history of the disease. The connection matters clinically because it suggests that the vascular and cardiac manifestations of Fabry disease are not parallel but unrelated processes; rather, they appear to be intertwined facets of a single progressive pathology. Endothelial dysfunction may contribute directly to the cardiac changes, by impairing coronary microvascular perfusion and promoting the fibrotic and hypertrophic remodeling of the myocardium, or both may simply reflect the burden of glycosphingolipid storage in different tissues. Either way, the measurement of endothelial function could serve as an early warning system for cardiac involvement.

Perhaps the most clinically consequential aspect of the study is its attention to sex differences. Because Fabry disease is X-linked, men—who carry only a single copy of the X chromosome—typically experience the disease in a severe, “classic” form, with essentially absent or nonfunctional alpha-galactosidase A, the enzyme whose deficiency causes lipid accumulation. Women, with two X chromosomes and random X-inactivation in each cell, usually have a mosaic of functional and dysfunctional cells, leading to a milder and later-onset course that has historically caused their disease to be underdiagnosed and undertreated. The Polish study’s data on how male and female patients differ in endothelial function and echocardiographic findings therefore carries weight beyond the numbers themselves: it reinforces the emerging consensus that Fabry disease in women is a real, progressive, and cardiologically relevant condition, not a benign carrier state.

The implications for patient management are considerable. Enzyme replacement therapy and the oral chaperone migalastat have transformed Fabry disease from an untreatable curiosity into a manageable chronic condition, but the timing of treatment initiation remains one of the field’s most debated questions. If endothelial dysfunction and early cardiac remodeling are already detectable in patients who have never had a cardiovascular event—as this study demonstrates—then the window for intervention may be narrower than many clinicians assume. Waiting for symptoms to appear may mean treating a cardiovascular system that has already sustained irreversible structural damage.

There are also methodological lessons in the study’s design. By excluding patients with prior cardiovascular events and matching controls on age, sex, and body mass index, the investigators sharpened the causal inference that Fabry disease itself drives the vascular and cardiac abnormalities. FMD, though technically demanding and subject to strict procedural requirements, remains among the most validated non-invasive windows into endothelial health; combining it with carotid IMT yields complementary functional and structural information. Pairing these vascular metrics with standard transthoracic echocardiography—widely available in routine clinical practice—means the assessment strategy described in this study could be adopted by metabolic and cardiology centers without exotic equipment.

The findings also resonate with a broader shift in cardiovascular medicine toward recognizing the endothelium as both a sentinel and a culprit. In diabetes, hypertension, chronic kidney disease, and now lysosomal storage disorders, the failure of the endothelial monolayer emerges as an early and quantifiable harbinger of downstream organ damage. For the global community of Fabry patients—estimated at roughly one in 40,000 to 60,000 men, with growing recognition that women are affected far more often than older textbooks suggested—studies like this one translate laboratory biochemistry into concrete clinical vigilance: measure the vessels, image the heart, and act before the damage becomes destiny.

As the Fabry research community continues to refine when and how to treat, this Polish cohort study provides a compelling argument that the blood vessels tell the story of the disease early, honestly, and in a sex-specific language that clinicians would do well to learn to read.